SG Americas Securities
ADAP

SG Americas Securities’s Adaptimmune Therapeutics ADAP Stock Holding History

SG Americas Securities’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-27,497
Closed -$4K – 3581
2025
Q3 		$4K Buy
+27,497
New +$3.77K ﹤0.01% 3334
2021
Q4 		– Sell
-85,163
Closed -$440K – 3336
2021
Q3 		$440K Sell
85,163
-150,551
-64% -$675K ﹤0.01% 2625
2021
Q2 		$1M Buy
235,714
+814
+0.3% +$3.95K ﹤0.01% 1553
2021
Q1 		$1.25M Buy
+234,900
New +$1.34M 0.01% 1373
2019
Q4 		– Sell
-21,987
Closed -$33K – 3256
2019
Q3 		$33K Sell
21,987
-1,272
-5% -$2.97K ﹤0.01% 2858
2019
Q2 		$94K Buy
23,259
+4,752
+26% +$19.4K ﹤0.01% 2821
2019
Q1 		$80K Sell
18,507
-1,497
-7% -$6.97K ﹤0.01% 3107
2018
Q4 		$115K Buy
20,004
+12,229
+157% +$90.2K ﹤0.01% 2656
2018
Q3 		$105K Sell
7,775
-13,123
-63% -$138K ﹤0.01% 2851
2018
Q2 		$248K Sell
20,898
-396
-2% -$4.94K ﹤0.01% 2464
2018
Q1 		$239K Buy
+21,294
New +$186K ﹤0.01% 2313

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

SG Americas Securities's ADAP Position: Q4 2025 in Review

SG Americas Securities sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 27,497 shares — an estimated $4K sold.

SG Americas Securities first reported a position in ADAP in Q1 2018 and held it in 11 quarters. The position peaked at $1.25M in Q1 2021. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • SG Americas Securities reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • SG Americas Securities sold 27,497 Adaptimmune Therapeutics shares in Q4 2025, an estimated $4K.
  • SG Americas Securities first reported a position in Adaptimmune Therapeutics in Q1 2018 and held it in 11 quarters.
  • SG Americas Securities's Adaptimmune Therapeutics position peaked at $1.25M in Q1 2021.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on SG Americas Securities's 13F filing for Q4 2025, filed 9 Jan 2026.